Media headlines about Shire (NASDAQ:SHPG) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group rates the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Shire earned a news impact score of 0.20 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 44.9662601968132 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:
- As Shire Plc (SHPG) Market Value Rose, Accipiter Capital Management Has Lifted by $1.98 Million Its Stake; Halcyon … – Hill Country Times (hillcountrytimes.com)
- Md Sass Investors Services Lowered By $23.03 Million Its Shire Plc (SHPG) Position; 3 Bullish Analysts Covering … – Hill Country Times (hillcountrytimes.com)
- Shire PLC (SHPG) Receives Average Recommendation of “Hold” from Brokerages (americanbankingnews.com)
- Zacks: Brokerages Anticipate Shire PLC (SHPG) to Post $3.86 EPS (americanbankingnews.com)
- Equities Analysts Set Expectations for Shire PLC’s FY2022 Earnings (SHPG) (americanbankingnews.com)
SHPG has been the topic of a number of research reports. Zacks Investment Research raised shares of Shire from a “sell” rating to a “hold” rating in a research report on Friday, October 27th. Royal Bank of Canada reaffirmed a “buy” rating on shares of Shire in a research report on Thursday, November 16th. Cantor Fitzgerald set a $222.00 target price on shares of Shire and gave the stock a “buy” rating in a research report on Thursday, November 16th. Cowen set a $225.00 target price on shares of Shire and gave the stock a “buy” rating in a research report on Sunday, October 29th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $245.00 target price on shares of Shire in a research report on Sunday, October 8th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and eight have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $212.18.
Shire (NASDAQ:SHPG) last announced its quarterly earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.64 by $0.17. The firm had revenue of $3.70 billion for the quarter. Shire had a net margin of 10.95% and a return on equity of 14.41%. The company’s quarterly revenue was up 7.1% compared to the same quarter last year. During the same period last year, the firm earned $3.17 EPS. sell-side analysts forecast that Shire will post 15 EPS for the current year.
TRADEMARK VIOLATION WARNING: “Shire (SHPG) Receiving Somewhat Favorable Press Coverage, Report Finds” was originally posted by Week Herald and is owned by of Week Herald. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://weekherald.com/2018/01/16/shire-shpg-receiving-somewhat-favorable-press-coverage-report-finds.html.
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.